Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Immunovia Full Year report 2019

February 14, 2020

“I am incredibly proud of the progress we made during 2019, especially in reaching the important milestone in December 2019 where we showed 95% accuracy for the upcoming commercialization of IMMray™ PanCan-d in diagnosing pancreatic cancer at a stage where it can still be operated on. This result opens the way for a significant improvement in care and an improved survival rate for patients suffering from this deadly disease. At Immunovia, we remain focused on introducing our blood-based test to the market in Q3 2020.

With two milestones remaining – a verification study and a final validation study – before the commercialization of IMMray™ technology in Q3 2020, we are intensifying the final launch preparations. We have successfully established a network of world renowned key opinion leaders and healthcare professionals to not only collaborate with us on how the test will be used in clinical practice, but also to supply us with the necessary blood samples, taken in the real clinical environment, to prove out IMMray™ technology. Our US team and those at the laboratory in Marlborough, MA are diligently working to implement logistics and distribution system that provides swift test results to support all our US customers. We have established a scalable sales and marketing organization which is targeting our key clinician customers at gastro centers around the US. Collaborations with patient organizations has also been a focus for us, as they play an important role in creating awareness and supporting the patients and their families.

We will market IMMray™ PanCan-d first in USA and then in Europe. We continue to increase the speed of our commercialization efforts for a successful launch of IMMray™ PanCan-d. Immunovia targets an initial addressable market of $4.4 BN USD in the US and Europe, and we look forward to working with healthcare providers around the world to improve the situation of this suffering patient group.”

Excerpt from the CEO Mats Grahn’s comment on the report.

Immunovia invites to a teleconference (in English) for investors, analysts and media on Friday, February 14th, 2020 at 8:30 am CET. Immunovia will publish the company’s Full Year 2019 report on February 14th, 2020 at 8:00 am CET.

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period Full Year 2019 Report followed by a Q&A session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Dial-in numbers:

Sweden: +46 (0) 8 50 520 424
United States: +1 212 999 6659
Austria: +43 (0) 12530807
Germany: +49 (0) 30 3001 90612
Denmark: +45 3271 4573
Switzerland: +41 (0) 22 592 7103
Spain: +34 91 787 0777
Netherlands: +31 (0) 20 794 8426
Norway: +47 2156 3318
France: +33 (0) 1 7037 7166
United Kingdom : +44 (0) 20 3003 2666

Conference code:

(To provide to the operator): Immunovia


For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia
Tel: +46 7 93 486 277

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on February 14, 2020.

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit


Full year report 2019 (PDF)